Proposal for research to reduce or eliminate mutagenic effects from a promising new anti-schistosomal drug

END PRODUCT IS FORMULATED COMPOUND WHICH CAN BE APPROVED FOR HUMAN TESTING. STUDIES INCLUDE SEARCH FOR METABOLITES RESPONSIBLE FOR SCHISTOSOMICIDAL ACTIVITY, DEVELOPMENT OF DRUG RESISTANCE IN SCHISTOSOMES, DETERMINATION OF HOW DRUG WORKS, DETECTION AND PREVENTION OF MUTAGENIC EFFECTS. WHEN INTESTINAL BACTERIA ARE ELIMINATED, NO MUTAGENIC MATERIAL IS FORMED AND DRUG EFFICACY IS NOT AFFECTED. 4 POSSIBLE TREATMENT METHODS ARE EXAMINED: REGULAR DOSE PRECEDED BY ELIMINATION OF INTESTINAL BACTERIA, USE OF ANALOG HAVING NO MUTAGENIC EFFECT, INJECTION OF DRUG TO BYPASS INTESTINES, COADMINISTRATION OF ANTICARCINOGENIC SUBSTANCES.